If he’s in HNW, he probably has had more face time with the CEO/management than us
Rohan and team has an iron conviction and faith that they’ll be able to alleviate a lot of suffering and be commercially successful ; it’s hard not to get a dose of this in a presentation they have a heart for translating the science to for their future patients and shareholders.
That said, we’re investing in intracellular intangible, outside looking in it seems v.risky hence the 10-20x expected payback your advisor is expecting - it’ll all become more solid when we see clinical data.
PYC, page-20
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $537.4K | 3.013M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 240589 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 76524 | 2 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |